Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080829 |
| Name | low grade glioma |
| Definition | A cell type benign neoplasm that has_material_basis_in glial cells (astrocytes, oligodendrocytes or ependymocytes). |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:0060101 |
| Path | disease disease of cellular proliferation benign neoplasm cell type benign neoplasm low grade glioma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600X | Dabrafenib | low grade glioma | predicted - sensitive | detail... |
| IDH1 mutant | Vorasidenib | low grade glioma | predicted - sensitive | detail... |
| IDH2 mutant | Vorasidenib | low grade glioma | predicted - sensitive | detail... |
| IDH1 R132H | Ivosidenib | low grade glioma | predicted - sensitive | detail... |
| IDH1 R132X | Ivosidenib | low grade glioma | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | low grade glioma | sensitive | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | low grade glioma | sensitive | detail... |
| BRAF fusion | Ulixertinib | low grade glioma | predicted - sensitive | detail... |
| BRAF V600X | Trametinib | low grade glioma | predicted - sensitive | detail... |
| BRAF V600X | Dabrafenib + Trametinib | low grade glioma | predicted - sensitive | detail... |
| FGFR1 act mut | Erdafitinib | low grade glioma | predicted - sensitive | detail... |
| FGFR1 K656E | Erdafitinib | low grade glioma | predicted - sensitive | detail... |
| BRAF V600E | FCN-159 | low grade glioma | predicted - sensitive | detail... |
| IDH1 act mut | Ivosidenib | low grade glioma | predicted - sensitive | detail... |
| IDH1 mutant | HMPL-306 | low grade glioma | predicted - sensitive | detail... |
| IDH2 mutant | HMPL-306 | low grade glioma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03585465 | Phase Ib/II | Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | Active, not recruiting | FRA | BEL | 0 |
| NCT04283669 | Phase II | Crizotinib | Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110) | Completed | USA | 0 |
| NCT04374305 | Phase II | Brigatinib | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2) | Active, not recruiting | USA | 0 |
| NCT04485559 | Phase I | Everolimus + Trametinib | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Recruiting | USA | 0 |
| NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Active, not recruiting | USA | CAN | 0 |
| NCT04773782 | Phase Ib/II | Avapritinib | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Active, not recruiting | USA | ITA | GBR | FRA | DEU | CAN | AUT | AUS | 1 |
| NCT04775485 | Phase II | Tovorafenib | A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1) | Recruiting | USA | NLD | ISR | GBR | DNK | DEU | CHE | CAN | AUS | 2 |
| NCT04923126 | Phase Ib/II | Mirdametinib | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
| NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Active, not recruiting | USA | 0 |
| NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Recruiting | FRA | 0 |
| NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People with Glioma | Recruiting | USA | 0 |
| NCT05222165 | Phase Ib/II | Infigratinib | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL) | Withdrawn | USA | DEU | CAN | 0 |
| NCT05303519 | Phase II | DS-1001b | Safusidenib Phase 2 Study in IDH1 Mutant Glioma | Recruiting | USA | 0 |
| NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
| NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Active, not recruiting | USA | 0 |
| NCT05566795 | Phase III | Tovorafenib | DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Recruiting | USA | SWE | SVN | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 6 |
| NCT05577416 | Phase I | DS-1001b | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (AB-218-IIT-201) | Recruiting | AUS | 0 |
| NCT05804227 | Phase I | Ulixertinib | Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas | Recruiting | USA | 0 |
| NCT06104488 | Phase I | RO5126766 | A Study of Avutometinib for People With Solid Tumor Cancers | Recruiting | USA | 0 |
| NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
| NCT06381570 | Phase I | Tovorafenib + Vinblastine | Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas (VICTORY) | Recruiting | CAN | 0 |
| NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DNK | CZE | 0 |
| NCT06636162 | Phase I | DSP-0390 | Window of Opportunity Study of DSP-0390 in Gliomas | Recruiting | USA | 0 |
| NCT07110246 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas (PNOC037) | Recruiting | USA | 0 |